EZH2 synergizes with BRD4-NUT to drive NUT carcinoma growth through silencing of key tumor suppressor genes

Abstract excerpt

<h4>ABSTRACT</h4> NUT carcinoma (NC) is an aggressive carcinoma driven by the BRD4-NUT fusion oncoprotein, which activates chromatin to promote expression of pro-growth genes. BET bromodomain inhibitors (BETi) impede BRD4-NUT’s ability to activate genes and are thus a promising treatment but limited as monotherapy. The role of gene repression in NC is unknown. Here, we demonstrate that EZH2, which silences genes...

Topics

Open a Topic to create a Post that cites this publication.

• Azepines
• Cyclin-Dependent Kinase 4
• Cyclin-Dependent Kinase 6
• E2F Transcription Factors
• Kruppel-Like Factor 4
• Monomeric GTP-Binding Proteins
• Neuroblastoma Research and Treatments
• Oncogene Proteins

Identifiers and source

Literature Corpus work

2d2d3ef3-c9c5-5b70-835b-fff48244afb5

DOI

10.1101/2023.08.15.553204